{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:41:40Z","timestamp":1792701700008,"version":"4.5.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Acute agitation is a frequent occurrence in both inpatient and outpatient psychiatric settings, and the use of medication to calm a patient may be warranted to mitigate the situation. Lorazepam is a benzodiazepine that is widely used for management of acute agitation. Despite its widespread use, there is remarkably little clinical evidence for the benefits of lorazepam in acute agitation. We performed a systematic review with focus on lorazepam, including all randomized clinical trials on lorazepam in mental and behavioral disorders, excluding studies on dementia and pediatric patients and in mixed conditions. A total of 11 studies met inclusion criteria, and all were in patients with mental and behavioral disorders. Most trials generally found improvements across a variety of outcomes related to agitation, although there was some disparity if specific outcomes were considered. In the five studies with haloperidol, the combination of lorazepam and haloperidol was superior to either agent alone, but with no differences between monotherapy with the individual agents. In the study comparing lorazepam to olanzapine, olanzapine was superior to lorazepam, and both were superior to placebo. As expected, the safety of lorazepam among the different studies was consistent with its well-characterized profile with dizziness, sedation, and somnolence being the most common adverse events. Based on this structured review, lorazepam can be considered to be a clinically effective means of treating the acutely agitated patient.<\/jats:p>","DOI":"10.3389\/fpsyt.2021.628965","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T05:07:58Z","timestamp":1613970478000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Treatment of Agitation With Lorazepam in Clinical Practice: A Systematic Review"],"prefix":"10.3389","volume":"12","author":[{"given":"Mario","family":"Amore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariella","family":"D'Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Fagiolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/15622975.2015.1132007","article-title":"Assessment and management of agitation in psychiatry: expert consensus","volume":"17","author":"Garriga","year":"2016","journal-title":"World J Biol Psychiatry."},{"key":"B2","first-page":"5","article-title":"The pathophysiology of agitation","author":"Lindenmayer","year":"2000","journal-title":"J Clin Psychiatry."},{"key":"B3","unstructured":""},{"key":"B4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.clinthera.2010.03.006","article-title":"Systematic reviews of assessment measures and pharmacologic treatments for agitation","volume":"32","author":"Zeller","year":"2010","journal-title":"Clin Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2165\/00003495-200565090-00003","article-title":"Pharmacological management of acute agitation","volume":"65","author":"Battaglia","year":"2005","journal-title":"Drugs."},{"key":"B6","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jemermed.2017.10.011","article-title":"Evidence-based review of pharmacotherapy for acute agitation. Part 1: Onset of Efficacy","volume":"54","author":"Zun","year":"2018","journal-title":"J Emerg Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2174\/1871527316666170919115507","article-title":"Older and newer strategies for the pharmacological management of agitation in patients with bipolar disorder or schizophrenia","volume":"16","author":"Amodeo","year":"2017","journal-title":"CNS Neurol Disord Drug Targets."},{"key":"B8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2165\/00023210-200822030-00002","article-title":"Pharmacological control of acute agitation: focus on intramuscular preparations","volume":"22","author":"Zimbroff","year":"2008","journal-title":"CNS Drugs."},{"key":"B9","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1177\/1039856213499620","article-title":"The comparative efficacy of intramuscular antipsychotics for the management of acute agitation","volume":"21","author":"Bosanac","year":"2013","journal-title":"Austr Psychiatry."},{"key":"B10","article-title":"Lorazepam","author":"Ghiasi","year":"2020"},{"key":"B11","doi-asserted-by":"publisher","first-page":"CD003079","DOI":"10.1002\/14651858.CD003079.pub4","article-title":"Benzodiazepines for psychosis-induced aggression or agitation","volume":"12","author":"Zaman","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3238\/arztebl.2019.0445","article-title":"The use of rapid tranquilization in aggressive behavior","volume":"116","author":"Hirsch","year":"2019","journal-title":"Dtsch Arztebl Int."},{"key":"B13","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ."},{"key":"B14","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ."},{"key":"B15","first-page":"177","article-title":"Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior","volume":"52","author":"Salzman","year":"1991","journal-title":"J Clin Psychiatry."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1176\/ajp.146.12.1598","article-title":"Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation","volume":"146","author":"Garza-Trevino","year":"1989","journal-title":"Am J Psychiatry."},{"key":"B17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/j.1875-9114.1998.tb03827.x","article-title":"A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation","volume":"18","author":"Bieniek","year":"1998","journal-title":"Pharmacotherapy."},{"key":"B18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0735-6757(97)90119-4","article-title":"Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study","volume":"15","author":"Battaglia","year":"1997","journal-title":"Am J Emerg Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/00004850-199705000-00009","article-title":"Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting","volume":"12","author":"Foster","year":"1997","journal-title":"Int Clin Psychopharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0735-6757(02)42249-8","article-title":"Calming versus sedative effects of intramuscular olanzapine in agitated patients","volume":"21","author":"Battaglia","year":"2003","journal-title":"Am J Emerg Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/JCP.0b13e318033bd5e","article-title":"Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole","volume":"27","author":"Zimbroff","year":"2007","journal-title":"J Clin Psychopharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"386","DOI":"10.4088\/JCP.v65n0315","article-title":"Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam","volume":"65","author":"Currier","year":"2004","journal-title":"J Clin Psychiatry."},{"key":"B23","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jfma.2015.01.018","article-title":"Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: an open-label, randomized controlled trial","volume":"114","author":"Huang","year":"2015","journal-title":"J Formos Med Assoc."},{"key":"B24","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1177\/070674370404900619","article-title":"Lorazepam-induced prolongation of the QT interval in a patient with schizoaffective disorder and complete AV block","volume":"49","author":"Ziegenbein","year":"2004","journal-title":"Can J Psychiatry."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1177\/0091270004267807","article-title":"Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia","volume":"44","author":"Harvey","year":"2004","journal-title":"J Clin Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.4103\/0970-9185.173335","article-title":"Ketamine-induced QTc interval prolongation","volume":"33","author":"Singh","year":"2017","journal-title":"J Anaesthesiol Clin Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/pds.3792","article-title":"Are ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? The example of haloperidol","volume":"24","author":"Warnier","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13104-015-1172-2","article-title":"Prescribing preferences in rapid tranquillisation: a survey in Belgian psychiatrists and emergency physicians","volume":"8","author":"Bervoets","year":"2015","journal-title":"BMC Res Notes."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.628965\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T05:08:01Z","timestamp":1613970481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.628965\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":28,"alternative-id":["10.3389\/fpsyt.2021.628965"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.628965","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,22]]},"article-number":"628965"}}